

## Disclosures

### Personal Commercial (11)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<b>Self</b>			
Alexion	Consultant Fees/Honoraria	Modest (< \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>
Amylin	Speaker's Bureau	Modest (< \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>
AstraZeneca Pharmaceuticals	Consultant Fees/Honoraria	Modest (< \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>
Eidos/BridgeBio	Consultant Fees/Honoraria	Modest (< \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>
Intellia	Consultant Fees/Honoraria	Modest (< \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>
Luminy	Consultant Fees/Honoraria	Modest (< \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>
Novo Nordisk Inc.	Consultant Fees/Honoraria	Significant (>= \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>
Pfizer	Consultant Fees/Honoraria	Modest (< \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>
Pfizer Inc	Research/Research Grants ‡ NCT05489523	Significant (>= \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>
Tenax Therapeutics	Data Safety Monitoring Board	Modest (< \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>
Ultramix	Consultant Fees/Honoraria	Modest (< \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>

### Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

### Personal Organizational or Other Non-Commercial (0)

No disclosures on record

### Clinical Trial Enroller (8)

Trial Name	Trial Sponsor	Trial Funding Source
Study of ALXN2220 Versus Placebo in Adults With ATTR-CM (DepleTTR-CM)	Alexion	
CARDIOTRansform	AstraZeneca Pharmaceuticals	
Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants	Eidos/BridgeBio	
ACT-EARLY	Eidos/BridgeBio	
MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)	Intellia	
An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)	Ionis / Astra-Zeneca	
MUSIC-HFrEF1	Sardocor	
MUSIC-HFrEF	Sardocor Corp.	

### Institutional Financial Decision-Making Role (0)

No disclosures on record

### Expert Witness Testimony (0)

No disclosures on record

‡ Commercial Funding Source | ‡ Trial Name

## Agreement

## **Confidentiality, Disclosure and Assignment Agreement** | Signed on 12/19/2025

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

## **Embargo** | Signed on 12/19/2025

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

## **On-Going Obligation Agreement** | Signed on 12/19/2025

---

### **ACC and Disclosures**

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.